Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 106, Issue 2, 1998, Pages 113-116

  Breidert, M ^a,d   Temelkova Kurktschiev, Th ^b   Hanefeld, M ^b   Leonhardt, W ^b   Schmoeckel, A ^b   Seissler, J ^c  

^a Dept of Int Med and Policlinic I ^*  (Germany)

^b Inst Policlinic Clin Metab R   (Germany)

^c LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

GAD antibodies,; IA 2 antibodies; IAA; ICA; Impaired glucose tolerance

Indexed keywords

AUTOANTIBODY; GLUCOSE; GLUTAMATE DECARBOXYLASE; PANCREAS ISLET CELL ANTIBODY; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PREVALENCE; PRIORITY JOURNAL;

EID: 0031960196     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211961     Document Type: Article

References (23)

1. Bingley PJ, Christie MR, Bonifacio E et al.: Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 43: 1304-1310, 1994
2. Edelstein SL, Knowler WL, Bain RP, Andres R, Barrett-Connor E, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF: Predictors of progression from impaired glucose tolerance to NIDDM. Diabetes 46: 701-710, 1997
3. Gottsäter A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkist G: β-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 16: 902-910, 1993
4. Groop LC, Bottazzo GF, Doniach D: Islet cell antibodies identify latent Type I diabetes in patients aged 35-75 years at diagnosis. Diabetes 35: 237-241, 1986
5. Harris MI: Impaired glucose tolerance in the U.S. population. Diabetes Care 12: 464-474, 1990
6. Irvine WJ, Sawers SA, Feek CM, Prescott RJ, Duncan LJP: The value of islet cell antibody in predicting secondary failure of oral hypoglycaemic agent therapy in diabetes mellitus. J Clin Lab Immunol 2: 23-26, 1979
7. Kobayashi T, Nakanishi K, Murase T, Kosaka K: Small doses of subcutaneous insulin as a strategy for preventing slowly progressive β-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45: 622-626, 1996
8. Kobayashi T, Nakanishi K, Okubo M, Murase T, Kosaka K: GAD antibodies seldom disappear in slowly progressive IDDM. Diabetes Care 19: 1031, 1996
9. Lohmann T, Seissler J, Verlohren HJ, Schröder S, Rötger J, Dähn K, Morgenthaler NG, Scherbaum WA: Distinct genetic and immunological features in patients with insulin-dependent diabetes below and above age 40 at onset. Diabetes Care 20: 524-529, 1997
10. Morgenthaler N, Seissler J, Achenbach P, Glawe D, Payton M, Meinck H, Christie M, Scherbaum WA: Antibodies to the Tyrosine phosphatase-like protein IA-2 are highly associated with IDDM, but not with autoimmune endocrine disease of Stiff Man syndrom. Autoimmunity 25: 202-212, 1997
11. Niskanen LK, Tuomi T, Kargalainen Y, Groop LF, Unsitupa MIY: GAD antibodies in NIDDM. Diabetes Care 18: 1557-1565, 1995
12. Riley WJ, MacLaren NK, Kirscher N et al.: A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N Engl J Med 323: 1167-1172, 1990
13. Roll U, Christie MR, Standl E, Ziegler A: Associations of anti-GAD antibodies with islet cell antibodies and insulin autoantibodies in first-degree relatives of Type 1 diabetic patients. Diabetes 43: 154-160, 1994
14. Ruige JB, Batstra M, Aanstoot H-J, Bouter LM, Bruining GJ, De Neeling JN, Heine RJ: Low prevalence of antibodies to GAD 65 in a 50 to 74 year-old general Dutch population. Diabetes Care 20: 1108-1110, 1997
15. Scherbaum WA, Mirakian R, Pujol-Borrell R, Dean BM, Bottazzo GF: Immunochemistry in the study and diagnosis of organ-specific autoimmune disease. In. Polak, JM, Van Noorden S (eds). Immunochemistry. Modern methods and applications, First Edition, pp. 456-476, Wright, Bristol, 1986
16. Seissler J, Morgenthaler NG, Achenbach P, Lampeter EF, Glawe D, Payton M, Christie M, Scherbaum WA and the DENIS Study Group: Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM. Diabetologia 39: 1351-1356, 1996
17. Service FY, Rizza RA, Zimmermann BR, Dyck PY, O'Brien PC, Melton III IY: The classification of diabetes by clinical and C-peptide criteria. Diabetes Care 20: 198-201, 1997
18. The Expert Committee on the Diagnosis and Classification of Diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20: 1183-1197, 1997
19. Vardi P, Ziegler AG, Matthews JH et al.: Concentrations of insulin autoantibodies at onset of type 1 diabetes: inverse log-linear correlation with age. Diabetes Care 11: 736-739, 1988
20. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase PH, Eisenbarth GS: Prediction of type 1 diabetes in first degree relatives using a combination of Insulin. GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45: 926-933, 1996
21. Wiest-Ladenburger U, Hartmann R, Hartmann U, Berling K, Boehm BO, Richter W: Combined analysis and single-step detection of GAD65 and IA-2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes 46: 565-571, 1997
22. World Health Organisation: Diabetes mellitus: Report of a WHO Study Group. Geneva, World Health Org. (Tech. Rep. Ser., No 727), 1985
23. Yassin N, Seissler J, Glück M, Boehm BO, Heinze E, Pfeiffer EF, Scherbaum WA: Insulin autoantibodies as determined by competitive radiobinding assay are positively correlated with impaired Beta cell function - The Ulm-Frankfurt population study. Klin Wochenschr. 69: 736-741, 1991